New experimental drug SYH2072 tested in humans for the first time
NCT ID NCT07647783
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing an experimental drug called SYH2072 in 112 healthy adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo as single or multiple doses. The study aims to gather basic safety information before the drug can be tested in patients with a disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SYH2072 tablets
- What this could lead to
- If this early study shows the drug is safe, it could pave the way for future trials testing SYH2072 in patients with a specific disease.
- What could go wrong
- This is a very early Phase 1 trial in healthy people, not patients. The drug may prove unsafe or ineffective in later studies. Side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Anzhen Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates